Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Combo bests single therapy in metastatic RCC

Motzer RJ et al. GU Cancers Symposium Abstract 578

Key clinical point: The combination of atezolizumab and bevacizumab is more efficacious than single-agent sunitinib as first-line therapy for metastatic RCC.

Major finding: Among patients with PD-L1-positive disease, median investigator-assessed progression-free survival was 11.2 months with atezolizumab-bevacizumab and 7.7 months with sunitinib (hazard ratio, 0.74; P = .02).

Data source: A randomized phase 3 trial among 915 patients with treatment-naive advanced or metastatic RCC (IMmotion151 trial).

Disclosures: Dr. Motzer disclosed that he has a consulting or advisory role with Pfizer, Novartis, Eisai, Exelixis, and Merck, and that his institution receives research funding from Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Eisai, Novartis, and Genentech/Roche. The study was sponsored by Genentech/Roche.

Source: Motzer RJ et al. GU Cancers Symposium Abstract 578

Citation:

Motzer RJ et al. GU Cancers Symposium Abstract 578

This Week's Must Reads

New model guides treatment decisions in mRCC, Armstrong AJ et al. Ann Oncol. 2018 Sep 10. doi: 10.1093/annonc/mdy406

mRCC: Jaw osteonecrosis increased with denosumab/antiangiogenics, Guillot A et al. Clin Genitourin Cancer. 2018 Sep 6. doi: 10.1016/j.clgc.2018.08.006.

Brazilian study: TKIs effective in clear cell RCC, Velho PI et al. J Glob Onc. 2018 Sep 10. doi: 10.1200/JGO.18.00073.

SBRT safe, effective in oligometastatic RCC, Franzese et al. J Urol. 2018 Sep 1. doi: 10.1016/j.juro.2018.08.049.

CRP levels and RCC prognosis, Nakayama T et al. Clin Genitourin Cancer. 2018 Aug 11. doi: 10.1016/j.clgc.2018.07.027.

Must Reads in Renal Cell Carcinoma

New model guides treatment decisions in mRCC, Armstrong AJ et al. Ann Oncol. 2018 Sep 10. doi: 10.1093/annonc/mdy406

mRCC: Jaw osteonecrosis increased with denosumab/antiangiogenics, Guillot A et al. Clin Genitourin Cancer. 2018 Sep 6. doi: 10.1016/j.clgc.2018.08.006.

Brazilian study: TKIs effective in clear cell RCC, Velho PI et al. J Glob Onc. 2018 Sep 10. doi: 10.1200/JGO.18.00073.

SBRT safe, effective in oligometastatic RCC, Franzese et al. J Urol. 2018 Sep 1. doi: 10.1016/j.juro.2018.08.049.

CRP levels and RCC prognosis, Nakayama T et al. Clin Genitourin Cancer. 2018 Aug 11. doi: 10.1016/j.clgc.2018.07.027.